Wolfe Research Maintains Outperform on Salesforce, Lowers Price Target to $180

Wolfe Research analyst Alex Zukin maintains Salesforce (NYSE:CRM) with a Outperform and lowers the price target from $200 to $180.

byBenzinga Newsdesk

September 23, 2022

1 minute read

Wolfe Research analyst Alex Zukin maintains Salesforce (NYSE:CRM) with a Outperform and lowers the price target from $200 to $180.

Tesla Falls On Q4 Earnings: 3 Analysts On What’s Next For EV Stock

By Shanthi Rexaline

Today, 9:52 AM

Tesla Inc (NASDAQ: TSLA) reported Wednesday with strong quarterly results, but the stock has not budged and is trading steep

TSLA

Greif Announces Definitive Agreement To Divest 50% Stake In Flexible Packaging Joint Venture To Gulf Refined Packaging For $123M

By Benzinga Newsdesk

Today, 9:52 AM

Greif, Inc. (NYSE:GEF, GEF.B)))), a global leader in industrial packaging products and services, announced today that it has entered into a definitive agreement to divest its 50% share in the Flexible

GEF

Spotify Breaks Out Of A Pattern And Moves Lower: What’s Next?

By Tyler Bundy

Today, 9:52 AM

Spotify Technology SA (NYSE: SPOT) shares are trading lower Thursday after the company reported fourth-quarter financial results and issued guidance.

SPOT

Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight, Announces $19 Price Target

By Benzinga Newsdesk

Today, 9:52 AM

Wells Fargo analyst Derek Archila upgrades Monte Rosa Therapeutics (NASDAQ:GLUE) from Equal-Weight to Overweight and announces $19 price target.

GLUE

Wolfe Research Maintains Outperform on Salesforce, Lowers Price Target to $180

Related Posts

Tesla Falls On Q4 Earnings: 3 Analysts On What’s Next For EV Stock

Greif Announces Definitive Agreement To Divest 50% Stake In Flexible Packaging Joint Venture To Gulf Refined Packaging For $123M

Spotify Breaks Out Of A Pattern And Moves Lower: What’s Next?

Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight, Announces $19 Price Target